Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01340885 · ClinicalTrials.gov registry record · Phase 4
Cognitive Decline in Non-demented PD
A Phase 4 study, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
NCT01340885 is a Phase 4 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 9 participants.
The verdict
NCT01340885, a Phase 4 study, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the relationship between attention and quality of life and how rivastigmine and atomoxetine alter attention in non-demented persons with Parkinson's disease (PD).
Interventions
- OTHER Placebo
- DRUG Strattera
- DRUG Exelon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2011-01 |
| Est. Completion | 2013-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01340885
The ClinicalTrials.gov registry entry for NCT01340885 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01340885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01340885 about?
NCT01340885 is a clinical study titled "Cognitive Decline in Non-demented PD". The purpose of this study is to determine the relationship between attention and quality of life and how rivastigmine and atomoxetine alter attention in non-demented persons with Parkinson's disease (PD).
What is the current status of trial NCT01340885?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2011-01. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01340885?
The interventions under investigation include: Placebo (OTHER), Strattera (DRUG), Exelon (DRUG).
Who is sponsoring clinical trial NCT01340885?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.